Search

Your search keyword '"Sonnerb̈org, A."' showing total 430 results

Search Constraints

Start Over You searched for: Author "Sonnerb̈org, A." Remove constraint Author: "Sonnerb̈org, A."
430 results on '"Sonnerb̈org, A."'

Search Results

2. Heavy antiretroviral exposure and exhausted/limited antiretroviral options: predictors and clinical outcomes

3. Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration

5. Novel tetra-peptide insertion in Gag-p6 ALIX-binding motif in HIV-1 subtype C associated with protease inhibitor failure in Indian patients

6. Heavy arv exposure and exhausted/limited arv options: predictors and clinical outcomes

8. Human APOBEC3G‐mediated hypermutation is associated with antiretroviral therapy failure in HIV‐1 subtype C‐infected individuals

9. The Human Immunodeficiency Virus Continuum of Care in European Union Countries in 2013: Data and Challenges

10. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy

12. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study

13. Naturally occurring dipeptide from elite controllers with dual anti-HIV-1 mechanism

14. Virologic Failure Following Low-level Viremia and Viral Blips During Antiretroviral Therapy: Results From a European Multicenter Cohort

15. Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents

16. Drug Resistance in Non-B Subtype HIV-1: Impact of HIV-1 Reverse Transcriptase Inhibitors

17. Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-naive individuals: results from a European multi-cohort study

18. Prevalence and Outcomes for Heavily Treatment-Experienced Individuals Living With Human Immunodeficiency Virus in a European Cohort

19. No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µL

20. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study

21. Incidence of cancer and overall risk of mortality in individuals treated with raltegravir‐based and non‐raltegravir‐based combination antiretroviral therapy regimens

22. The extent of B‐cell activation and dysfunction preceding lymphoma development in HIV‐positive people†

23. CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study

24. No need for secondary Pneumocystis jirovecii pneumonia prophylaxis in adult people living with HIV from Europe on ART with suppressed viraemia and a CD4 cell count greater than 100 cells/µL

25. Transmission of Drug-Resistant HIV-1 Is Stabilizing in Europe

26. Multi-omics personalized network analyses highlight progressive disruption of central metabolism associated with COVID-19 severity

27. Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium

28. Effectiveness of integrase strand transfer inhibitors in HIV-infected treatment-experienced individuals across Europe

29. Spectrum of Atazanavir-Selected Protease Inhibitor-Resistance Mutations

30. The Health Gym: synthetic health-related datasets for the development of reinforcement learning algorithms

31. Integrase Strand Transfer Inhibitor Use and Cancer Incidence in a Large Cohort Setting

32. Molecular Epidemiology of HIV-1 in Eastern Europe and Russia

34. Observational cohort study of rilpivirine (RPV) utilization in Europe

35. Impact of Therapeutic Immunization on HIV-1 Viremia after Discontinuation of Antiretroviral Therapy Initiated during Acute Infection

36. Human immunodeficiency virus continuum of care in 11 european union countries at the end of 2016 overall and by key population: Have we made progress?

37. Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?

38. HCV reinfection after HCV therapy among HIV/HCV-coinfected individuals in Europe

39. Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE

40. Gender differences in the use of cardiovascular interventions in HIV?positive persons; the D:A:D Study

41. Efficacy and Safety of Antiretroviral Therapy Initiated One Week after Tuberculosis Therapy in Patients with CD4 Counts < 200 Cells/μL: TB-HAART Study, a Randomized Clinical Trial.

42. Efficacy of etravirine combined with darunavir or other ritonavir-boosted protease inhibitors in HIV-1-infected patients: an observational study using pooled European cohort data*

43. Peripheral blood CD4+CCR6+ compartment differentiates HIV-1 infected or seropositive elite controllers from long-term successfully treated individuals

44. Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co-infected HIV patients with cirrhosis

45. Temporal trends in the Swedish HIV-1 epidemic: increase in non-B subtypes and recombinant forms over three decades.

47. The effect of primary drug resistance on CD4 cell decline and the viral load set-point in HIV-positive individuals before the start of antiretroviral therapy

48. Optimal probability weights for estimating causal effects of time-varying treatments with marginal structural Cox models

49. Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus co-infected HIV patients with cirrhosis

50. Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

Catalog

Books, media, physical & digital resources